Inhalation Sciences
Novomirgorod · Founded 2004
About Inhalation Sciences
The PreciseInhale patented aerosol generation R&D platform delivers respirable dry powder aerosols from preclinical cell studies all the way through to human clinical trials, significantly accelerating drug development timelines. The platform’s one-animal-at-a-time system requires just milligrams, not grams of costly test substance for a full PK study and delivers high-resolution lung data of, typically, <10% SD. We carry out Contract Research for novel and generic inhalation drug developers, toxicology and environmental research institutes and university research institutes in the inhalation and aerosolization field.
Company Facts
- Founded: 2004
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.2M
- Funding stage: IPO
- Last round: Grant (May 2023)
- Ticker: ngm:ISAB
- Website: http://www.inhalation.se/
- Phone: +460706450875
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inhalation-sciences-2240239 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.